Correspondence | Published:

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo

Nature Methods volume 15, page 237 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    et al. Nat. Methods 14, 547–548 (2017).

  2. 2.

    et al. Mol. Ther. 24, 1388–1394 (2016).

  3. 3.

    et al. Genome Biol. 13, R72 (2012).

  4. 4.

    et al. Nat. Biotechnol. 34, 184–191 (2016).

  5. 5.

    , , , & Epigenetics Chromatin 8, 54–65 (2015).

  6. 6.

    et al. Nat. Methods 12, 479 (2015).

  7. 7.

    & Cell 168, 644–656 (2017).

Download references

Author information

Affiliations

  1. Intellia Therapeutics, Inc. Cambridge, Massachusetts, USA.

    • Reynald M Lescarbeau
    • , Bradley Murray
    • , Thomas M Barnes
    •  & Nessan Bermingham

Authors

  1. Search for Reynald M Lescarbeau in:

  2. Search for Bradley Murray in:

  3. Search for Thomas M Barnes in:

  4. Search for Nessan Bermingham in:

Competing interests

The authors are employees of and stockholders in Intellia Therapeutics, Inc.

Corresponding authors

Correspondence to Reynald M Lescarbeau or Thomas M Barnes.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–2, Supplementary Tables 1–3 and Supplementary Methods

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nmeth.4553